CIK 0001549595 · Large accelerated filer
Nurix Therapeutics, Inc.
Sign in to watch- Ticker
- NRIX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Nov 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 270838048
- Phone
- (415) 660-5320
- Business address
- 1600 SIERRA POINT PKWY, BRISBANE, CA, 94005
- Former names
- Nurix, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,712,859
- in 10 filings, $1.0M under 10b5-1 plans
Net −$1,712,859. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-30 | Ring Christine Chief Legal Officer | Sale | −3,957 | $26.28 | $104K | 15,335 |
| 2026-10-30 | Ring Christine Chief Legal Officer | Option exercise · Restricted Stock Units | −3,750 | 7,500 | ||
| 2026-10-30 | Ring Christine Chief Legal Officer | Option exercise · Restricted Stock Units | −2,859 | 17,150 | ||
| 2026-10-30 | Ring Christine Chief Legal Officer | Option exercise · Restricted Stock Units | −3,573 | 35,730 | ||
| 2026-10-30 | Hansen Gwenn Chief Scientific Officer | Option exercise 10b5-1 | +3,750 | 120,977 | ||
| 2026-10-30 | Hansen Gwenn Chief Scientific Officer | Option exercise 10b5-1 | +2,859 | 123,836 | ||
| 2026-10-30 | Hansen Gwenn Chief Scientific Officer | Option exercise 10b5-1 | +3,573 | 127,409 | ||
| 2026-10-30 | Hansen Gwenn Chief Scientific Officer | Sale 10b5-1 | −3,957 | $26.28 | $104K | 123,452 |
| 2026-10-30 | Hansen Gwenn Chief Scientific Officer | Option exercise · Restricted Stock Units 10b5-1 | −3,750 | 7,500 | ||
| 2026-10-30 | Hansen Gwenn Chief Scientific Officer | Option exercise · Restricted Stock Units 10b5-1 | −2,859 | 17,150 | ||
| 2026-10-30 | Hansen Gwenn Chief Scientific Officer | Option exercise · Restricted Stock Units 10b5-1 | −3,573 | 35,730 | ||
| 2026-10-15 | Hansen Gwenn Chief Scientific Officer | Option exercise 10b5-1 | +1,452 | $1.86 | $3K | 118,679 |
| 2026-10-15 | Hansen Gwenn Chief Scientific Officer | Sale 10b5-1 | −1,452 | $25.00 | $36K | 117,227 |
| 2026-10-15 | Hansen Gwenn Chief Scientific Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −1,452 | 59,406 | ||
| 2026-10-14 | GREGORY JULIA P Director | Option exercise | +22,583 | $1.86 | $42K | 33,333 |
| 2026-10-14 | GREGORY JULIA P Director | Sale | −22,583 | $23.40 | $529K | 10,750 |
| 2026-10-14 | GREGORY JULIA P Director | Option exercise · Director Stock Option (right to buy) | −22,583 | 0 | ||
| 2026-10-02 | Ring Christine Chief Legal Officer | Option exercise 10b5-1 | +5,786 | $8.72 | $50K | 14,896 |
| 2026-10-02 | Ring Christine Chief Legal Officer | Sale 10b5-1 | −5,786 | $23.19 | $134K | 9,110 |
| 2026-10-02 | Ring Christine Chief Legal Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −5,786 | 111,251 |
Page 2 of 20 · 381 trades